All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses

Author(s): P Selvam1, N Murgesh2, M Chandramohan3, E De Clercq4, E Keyaerts4, L Vijgen4, P Maes4, J Neyts4, MV Ranst4
1Arulmigu Kalasalingam College of Pharmacy, Krishnankoil - 626 190, India 2Institute of Pharmacology, Madurai Medical College, Madurai - 625 020, India 3Bharat Ratna Kamarajar Liver Hospital and Research Center, Madurai - 625 001, India 4Raga Institute for Medical Research, Katholieke Universiteit-Leuven, Minder broederstraat 10, LeuvenB-3000, Belgium

Correspondence Address:
P Selvam, Arulmigu Kalasalingam College of Pharmacy, India, E-mail: [email protected]


4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)benzene sulphonamide and its derivatives were evaluated for antiviral activity against Pathogenic viruses such as Hepatitis C Virus and SARS-CoV in Vero and Huh 5-2 cells, respectively. The 5-fluoro derivative inhibited the HCV RNA synthesis at 6 µg/ml, without toxicity at a concentration up to 42 µg/ml in Huh 5-2 cells. Among the compounds tested SPIII-5F exhibits the 45% maximum protection against replication of SARS-CoV in Vero cells.



Share this